Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group.

Abstract

Combining either 800 or 400 mg per day pazopanib with standard carboplatin/paclitaxel chemotherapy is not a feasible treatment option.

Full Text

• DOI - British journal of cancer (DOI)
• Swets Information Services - full-text online
• Nature Publishing Group - full-text online
• EBSCO - full-text online

Subjects

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Carboplatin
• Early Termination of Clinical Trials
• Feasibility Studies
• Female
• Genital Neoplasms, Female
• Humans
• Middle Aged
• Paclitaxel
• Pyrimidines
• Sulfonamides

Similar articles

• Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. (2013-02-04)
• Pazopanib and Paclitaxel synergize in anaplastic thyroid cancer. (2013-01-10)
• Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study. (2006-02-28)
• Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer. (2013-04-12)
• Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. (2013-01-03)
• A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). (2012-12-09)
• A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. (2013-03-05)
• Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. (2007-06-18)
• Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. (2012-11-05)

Authors

• A du Bois
• I Vergote
• P Wimberger
• I Ray-Coquard
• P Harter
• L B Curtis
• I Mitrica

Publication date

2012-02-15

Journal

Journal topics

• Neoplasms

Language

Eng.

Copyright

British journal of cancer

Departments of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany. prof.dubois [at] googlemail.com

Release reference

Br J Cancer. 2012 Feb;106(4):629-32

Related books

• Books of Antineoplastic Combined Chemotherapy Protocols
• Books of Carboplatin
• Books of Early Termination of Clinical Trials
• Books of Feasibility Studies
• Books of Genital Neoplasms, Female
• Books of Neoplasms
• Books of Paclitaxel
• Books of Pyrimidines
• Books of Sulfonamides